First details of lurasidone's Phase III efficacy in bipolar depression

01:35 EST 6 Nov 2013 | SCRIP

In June, the multi-modal molecule became the first atypical antipsychotic to be approved for use in the US for adults with major depressive episodes associated with bipolar I disorder, both as a monotherapy and an adjunctive therapy to the mood...

Original Article: First details of lurasidone's Phase III efficacy in bipolar depression

NEXT ARTICLE

More From BioPortfolio on "First details of lurasidone's Phase III efficacy in bipolar depression"

Search BioPortfolio:
Advertisement
Advertisement

Searches Linking to this Story